TearLab Gets FDA 510(k) Approval
TearLab Corporation has received FDA 510(k) clearance of its TearLab Osmolarity System.
TearLab Corporation has received FDA 510(k) clearance of its TearLab Osmolarity System.
BioNeutral Group, a developer of chemical-based technology, announced that they will form a new wholly owned subsidiary in Hong Kong to commercialize their proprietary chemical formulations throughout Asia.
Bioject Medical Technologies, a developer of needle-free injection systems, has signed a cooperative R&D agreement with the U.S. Navy to use Bioject’s technology in a malaria vaccine the Navy is developing.
Eight studies presented this week at the American Urological Association Annual Meeting suggest that Gen-Probe’s investigational test for the prostate cancer gene PCA3 may address some of the major challenges faced by urologists when diagnosing the disease.
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
Two strong players in the surgical-instrument field have joined forces. Microline PENTAX, a leading manufacturer of reposable surgical instruments for laparoscopic procedures, has acquired California-based Starion Instruments, a developer of instruments to arrest bleeding during surgical procedures.
Sunshine Heart, a global company that develops cardiac assist devices, has successfully completed the first two implants of the company’s C-Pulse heart assist system under a 20-person clinical trial approved by the U.S. Food and Drug Administration.
Symphony Medical, a developer of novel biopolymer technologies for cardiac disorders, has successfully used its flagship Algisyl-LVR technology to treat their first human patient.
The idea of putting electrodes on one’s eyelids might cause many to cringe, but ScyFIX of Minnesota is turning this odd concept into a promising treatment for age-related vision loss.
Many patients are left humiliated and depressed because of the daily disruptions caused by urinary or fecal incontinence. Vermont company AugmentRX is developing incontinence solutions for the 200 million-plus people worldwide who suffer from this debilitating condition.
Copyright © 2024 | WordPress Theme by MH Themes